UroToday - UroToday :: The Clinical Efficacy of Tolterodine Extended-Release is Maintained for 24 h in Patients with Overactive Bladder

The Clinical Efficacy of Tolterodine Extended-Release is Maintained for 24 h in Patients with Overactive Bladder - Abstract

Friday, 17 August 2007

Department of Urology, Vanderbilt University Medical Center, Nashville, TN 37232, USA. This email address is being protected from spam bots, you need Javascript enabled to view it

To assess the 24-h efficacy of tolterodine extended-release (ER) in patients with overactive bladder (OAB) and urgency urinary incontinence (UUI).

We conducted a post hoc analysis of a 12-week, placebo-controlled trial of tolterodine-ER in patients with frequency (> or =8 voids/24 h) and UUI (> or=5 episodes/week) for > or = 6 months. Seven-day bladder diaries were used to record diary endpoints; 24-h diary data were stratified by 6-h periods beginning at midnight.

Compared with placebo (508 patients), tolterodine-ER (507 patients) significantly and consistently increased volume voided per void and reduced UUI episodes and micturition frequency during each interval.

These results indicate that tolterodine-ER maintained clinical efficacy over 24 h and should be effective for OAB symptoms without regard to whether symptoms occur during the day or at night.

Written by Dmochowski R, Kreder K, MacDiarmid S, Carlsson M, Guan Z.

Reference

BJU Int. 2007 Jul;100(1):107-10

Reader Comments

Please log-in or register in order to submit comments.